These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 11223988)

  • 1. Persistent, antigen-specific, therapeutic antitumor immunity by dendritic cells genetically modified with an adenoviral vector to express a model tumor antigen.
    Song W; Tong Y; Carpenter H; Kong HL; Crystal RG
    Gene Ther; 2000 Dec; 7(24):2080-6. PubMed ID: 11223988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HER-2/neu-gene engineered dendritic cell vaccine stimulates stronger HER-2/neu-specific immune responses compared to DNA vaccination.
    Chan T; Sami A; El-Gayed A; Guo X; Xiang J
    Gene Ther; 2006 Oct; 13(19):1391-402. PubMed ID: 16724093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor regression induced by intratumor administration of adenovirus vector expressing CD40 ligand and naive dendritic cells.
    Kikuchi T; Miyazawa N; Moore MA; Crystal RG
    Cancer Res; 2000 Nov; 60(22):6391-5. PubMed ID: 11103803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adenovirus-mediated CD40 ligand gene-engineered dendritic cells elicit enhanced CD8(+) cytotoxic T-cell activation and antitumor immunity.
    Liu Y; Zhang X; Zhang W; Chen Z; Chan T; Ali K; Jia Z; Xiang J
    Cancer Gene Ther; 2002 Feb; 9(2):202-8. PubMed ID: 11857039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity.
    Song W; Kong HL; Carpenter H; Torii H; Granstein R; Rafii S; Moore MA; Crystal RG
    J Exp Med; 1997 Oct; 186(8):1247-56. PubMed ID: 9334364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dendritic cells modified to express fractalkine/CX3CL1 in the treatment of preexisting tumors.
    Nukiwa M; Andarini S; Zaini J; Xin H; Kanehira M; Suzuki T; Fukuhara T; Mizuguchi H; Hayakawa T; Saijo Y; Nukiwa T; Kikuchi T
    Eur J Immunol; 2006 Apr; 36(4):1019-27. PubMed ID: 16525992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activation of cancer patient-derived dendritic cells by tumor cells genetically modified to express CD154.
    Loskog A; Tötterman TH; Böhle A; Brandau S
    Cancer Gene Ther; 2002 Oct; 9(10):846-53. PubMed ID: 12224026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human PBMC-derived dendritic cells transduced with an adenovirus vectorinduce cytotoxic T-lymphocyte responses against a vector-encoded antigen in vitro.
    Diao J; Smythe JA; Smyth C; Rowe PB; Alexander IE
    Gene Ther; 1999 May; 6(5):845-53. PubMed ID: 10505110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Macrophage-derived chemokine gene transfer results in tumor regression in murine lung carcinoma model through efficient induction of antitumor immunity.
    Guo J; Wang B; Zhang M; Chen T; Yu Y; Regulier E; Homann HE; Qin Z; Ju DW; Cao X
    Gene Ther; 2002 Jun; 9(12):793-803. PubMed ID: 12040461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Injection of IL-12 gene-transduced dendritic cells into mouse liver tumor lesions activates both innate and acquired immunity.
    Tatsumi T; Takehara T; Yamaguchi S; Sasakawa A; Miyagi T; Jinushi M; Sakamori R; Kohga K; Uemura A; Ohkawa K; Storkus WJ; Hayashi N
    Gene Ther; 2007 Jun; 14(11):863-71. PubMed ID: 17344900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dendritic cell-tumor cell hybrids enhance the induction of cytotoxic T lymphocytes against murine colon cancer: a comparative analysis of antigen loading methods for the vaccination of immunotherapeutic dendritic cells.
    Yasuda T; Kamigaki T; Nakamura T; Imanishi T; Hayashi S; Kawasaki K; Takase S; Ajiki T; Kuroda Y
    Oncol Rep; 2006 Dec; 16(6):1317-24. PubMed ID: 17089056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo gene transfer of CD40 ligand into colon cancer cells induces local production of cytokines and chemokines, tumor eradication and protective antitumor immunity.
    Sun Y; Peng D; Lecanda J; Schmitz V; Barajas M; Qian C; Prieto J
    Gene Ther; 2000 Sep; 7(17):1467-76. PubMed ID: 11001366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dendritic cells engineered to express the Flt3 ligand stimulate type I immune response, and induce enhanced cytoxic T and natural killer cell cytotoxicities and antitumor immunity.
    Liu Y; Huang H; Chen Z; Zong L; Xiang J
    J Gene Med; 2003 Aug; 5(8):668-80. PubMed ID: 12898636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dendritic cell therapy with interferon-alpha synergistically suppresses outgrowth of established tumors in a murine colorectal cancer model.
    Ishii S; Hiroishi K; Eguchi J; Hiraide A; Imawari M
    Gene Ther; 2006 Jan; 13(1):78-87. PubMed ID: 16107857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of ErbB-2/neu-specific protective and therapeutic antitumor immunity using genetically modified dendritic cells: enhanced efficacy by cotransduction of gene encoding IL-12.
    Chen Y; Emtage P; Zhu Q; Foley R; Muller W; Hitt M; Gauldie J; Wan Y
    Gene Ther; 2001 Feb; 8(4):316-23. PubMed ID: 11313806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Enhanced antitumor effects induced by lymphotactin gene-modified dendritic cells after pulsed with tumor antigen peptide].
    Zhang W; He L; Cao X
    Zhonghua Yi Xue Za Zhi; 1999 Mar; 79(3):170-3. PubMed ID: 11601032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lymphotactin gene-modified bone marrow dendritic cells act as more potent adjuvants for peptide delivery to induce specific antitumor immunity.
    Cao X; Zhang W; He L; Xie Z; Ma S; Tao Q; Yu Y; Hamada H; Wang J
    J Immunol; 1998 Dec; 161(11):6238-44. PubMed ID: 9834111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic and specific antitumor immunity induced by co-administration of immature dendritic cells and adenoviral vector expressing biologically active IL-18.
    Tanaka F; Hashimoto W; Robbins PD; Lotze MT; Tahara H
    Gene Ther; 2002 Nov; 9(21):1480-6. PubMed ID: 12378411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The systemic administration of Ig-4-1BB ligand in combination with IL-12 gene transfer eradicates hepatic colon carcinoma.
    Xu DP; Sauter BV; Huang TG; Meseck M; Woo SL; Chen SH
    Gene Ther; 2005 Oct; 12(20):1526-33. PubMed ID: 15973445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.